Cognition announces outcomes from trial of zervimesine for geographic atrophy
Cognition Therapeutics has announced positive topline outcomes from the double-masked Phase II MAGNIFY trial of zervimesine (CT1812) in adult patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD).
The placebo-controlled study was completed following the enrolment of approximately 100 of the planned 246 subjects. It used two measures to assess the change in GA lesions: growth rate and size.
Subjects were evaluated for tolerability and safety, GA lesion size and growth rate changes, visual acuity changes, and other visual and anatomic measures.
According to the company, a slope analysis indicated that the GA trajectory had slowed by 28.6% in patients treated with zervimesine. In addition, at 18 months, the mean lesion size for those treated with zervimesine was 28.2% smaller than that of the placebo group.
Nearly two-thirds of subjects completed one year of dosing, and one-third completed 18 months.
While additional data on demographics, safety, and visual and anatomic outcomes are still under analysis, the company plans to present the complete findings at a medical meeting later in the year.
GA is marked by the formation of lesions consisting of dead retinal cells and undegraded waste proteins, leading to central vision blind spots.
In the trial, subjects were randomised and were given either a placebo or 200mg of oral zervimesine once a day.
The voluntary conclusion of the study enabled Cognition to redirect resources towards its ongoing Alzheimer's and dementia with lewy bodies (DLB) programmes.
Cognition Therapeutics research and development head and chief medical officer Anthony Caggiano said: 'To date, we have observed evidence of robust slowing of disease progression with zervimesine treatment in Phase II studies in Alzheimer's disease and dementia with Lewy bodies.
'These results in dry AMD represent yet another indication in which zervimesine has potential to slow the progression of disease with a once-daily oral pill. Compared to current treatment options, which require regular clinic visits for intravitreal injections, an effective oral treatment that patients can take at home would be truly transformative.'
In April last year, the company completed subject enrolment in its Phase II SHIMMER trial of CT1812 for treating mild-to-moderate DLB.
"Cognition announces outcomes from trial of zervimesine for geographic atrophy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Bill Gates reveals 'next phase of Alzheimer's fight' as he shares dad's personal battle
Bill Gates is speaking out about his personal experience with Alzheimer's — and his hope for progress in fighting the disease. In an essay published this week on his blog at the Microsoft co-founder and tech billionaire, 69, reflected on the difficulty of spending another Father's Day without his dad, Bill Gates Sr. The elder Gates passed away in 2020 at the age of 94 after battling Alzheimer's. Rates Of Dementia Are Lower In People Who Eat This Specific Diet, Research Shows "It was a brutal experience, watching my brilliant, loving father go downhill and disappear," Gates wrote in the blog post. Today, motivated by his own experience with the common dementia, Gates — who serves as chair of the Gates Foundation — is committed to working toward a cure for the common dementia, which currently affects more than seven million Americans, or one in nine people over 65. Read On The Fox News App In his blog, Gates expressed optimism about the "massive progress" being made in the fight against Alzheimer's and other dementias. Last year, Gates said he visited Indiana University's School of Medicine in Indianapolis to tour the labs where teams have been researching Alzheimer's biomarkers. Bill Gates Likely Had Autism As A Child, He Reveals: 'Wasn't Widely Understood' "I also got the opportunity to look under the hood of new automated machines that will soon be running diagnostics around the world," he wrote. "It's an exciting time in a challenging space." One of the biggest breakthroughs in Alzheimer's research, according to Gates, is blood-based diagnostic tests, which detect the ratio of amyloid plaques in the brain. (Amyloid plaques, clumps of protein that accumulate in the brain, are one of the hallmarks of Alzheimer's.) "I'm optimistic that these tests will be a game-changer," Gates wrote. Last month, the U.S. Food and Drug Administration (FDA) approved the first blood-based test for patients 55 years and older, as Fox News Digital reported at the time. Traditionally, Gates noted, the primary path to Alzheimer's diagnosis was either a PET scan (medical imaging) or spinal tap (lumbar puncture), which were usually only performed when symptoms emerged. The hope is that blood-based tests could do a better job of catching the disease early, decline begins. "We now know that the disease begins 15 to 20 years before you start to see any signs," Gates wrote. "A simple, accurate and easy-to-run blood test might one day make routine screening possible, identifying patients long before they experience cognitive decline," he stated. Gates said he is often asked, "What is the point of getting diagnosed if I can't do anything about it?" To that end, he expressed his optimism for the future of Alzheimer's treatments, noting that two drugs — Lecanemab (Leqembi) and Donanemab (Kisunla) — have gained FDA approval. "Both have proven to modestly slow down the progression of the disease, but what I'm really excited about is their potential when paired with an early diagnostic," Gates noted. He said he is also hopeful that the blood tests will help speed up the process of enrolling patients in clinical trials for new Alzheimer's drugs. To accomplish this, Gates is calling for increased funding for research, which often comes from federal grants. Click Here To Sign Up For Our Health Newsletter "This is the moment to spend more money on research, not less," he wrote, also stating that "the quest to stop Alzheimer's has never had more momentum." "There is still a huge amount of work to be done — like deepening our understanding of the disease's pathology and developing even better diagnostics," Gates went on. Gates pointed out that when his father had Alzheimer's, it was considered a "death sentence," but that is starting to change. "I am blown away by how much we have learned about Alzheimer's over the last couple of years," he wrote. For more Health articles, visit "I cannot help but be filled with a sense of hope when I think of all the progress being made on Alzheimer's, even with so many challenges happening around the world. We are closer than ever before to a world where no one has to watch someone they love suffer from this awful disease."Original article source: Bill Gates reveals 'next phase of Alzheimer's fight' as he shares dad's personal battle
USA Today
8 hours ago
- USA Today
When Caregiving Becomes Identity: Lynn Wenger's Real, Raw Journey Through Alzheimer's
What does it mean to love someone slowly forgetting who you are? For Lynn Wenger, the author of A Husband's Memoir: A Journey Through Alzheimer's, love wasn't just about showing up in the early days for his wife. It was about staying even when the person you knew began to fade, and every familiar rhythm was replaced with uncertainty. In the book, Lynn pulls back the curtain on a quiet transformation that took place when his wife was diagnosed with early-onset Alzheimer's at just 59 years old. He transformed from a devoted husband into a full-time caregiver, and that shift ultimately cost him. Before all this, Lynn was a self-made man from rural Iowa who built a successful career in construction consulting. Wendy was a registered nurse with a quick wit and a huge heart. She was the kind of person who showed up for her friends, volunteered at the local preschool, and still made time for church choir and book club. Together, they raised a family, built a life, and shared memories. This memoir, written in the months and years following his wife Wendy's diagnosis, isn't just about navigating the realities of Alzheimer's. It's about identity, grief, and what happens until you can't tell where love ends and caregiving begins. A Role He Never Trained For Lynn is no stranger to structure. He's a scheduler and a planner — someone who ran multi-million-dollar construction jobs with near-photographic precision. However, not even decades of professional precision or life experience could prepare him for the difficulties of caregiving. The shift from partner to caregiver was instantaneous and irreversible. Conversations grew harder. Decisions became heavier. "I wasn't just helping her," Lynn writes. "I was feeding her, dressing her, calming her down, watching for the next meltdown, trying to hold her world together while mine was quietly falling apart." The Isolation No One Sees In the outside world, Lynn kept things moving — balancing his work, organizing church events, staying involved in their local Boy Scout troop, and checking in with neighbors. But behind closed doors, life was shrinking. Time for himself became non-existent. So did the ability to sleep through the night. He wasn't just managing Wendy's care; he was carrying the emotional weight of every change. Her moods. Her confusion. Her sudden fear of water, loud noises, or unfamiliar places. Her eventual inability to recognize their own home. "There were days I couldn't even leave the room," Lynn writes. "Not because I had nowhere to go, but because she didn't want to let go of my hand." Lynn describes the kind of loneliness that only caregivers know, where you're never physically alone but constantly longing for a connection that used to be effortless. A Grief That Starts Too Soon In his reflections, Lynn speaks to a grief that begins long before a life ends. As Wendy's cognitive decline accelerated, moments of clarity became rare and precious. She could still sing along to their favorite 70s music. She could still flash her signature sense of humor. But those sparks were fleeting. "You don't just grieve the person," Lynn explains. "You grieve your life together. The future you planned. The roles you once shared." He captures the irony of being both deeply needed and gradually invisible — of loving someone who no longer knows they love you back. Regret, Real Talk, and a Little Grace Lynn's story is the unmistakable voice of a man doing his best. But also, the honesty of a man who wrestles with guilt. Guilt for the moments he spent working instead of sitting by her side. Guilt for the times he didn't recognize a symptom until it was too late. Guilt for simply needing a break. "If I could go back," he writes, "I'd trade every spreadsheet and scout meeting for one more walk around the block with her." However, Lynn doesn't let bitterness cloud his writing; he shares a unique perspective. Lynn's regrets are balanced by deep wells of grace, reminding caregivers everywhere that they're human — and doing more than enough. A Husband's Memoir: A Journey Through Alzheimer's does more than tell one couple's story. It shines a light on the hidden world of caregiving and how it involves sacrifice, resilience, humor, and heartbreak. Lynn doesn't gloss over the hard parts. Instead, he shares them so that others might feel less alone. Where Lynn Is Now Wendy passed away in early 2024 at just 64 years old. Lynn has since become an advocate for Alzheimer's awareness, supporting research and helping organize his local Walk to End Alzheimer's. He's been approached about leading support groups, especially for husbands and partners who, like him, never expected to become full-time caregivers. And he's open about the fact that he's still grieving, still figuring it all out. 'People think the hard part ends when they pass,' he says. 'But grief has its own timeline. It doesn't check your calendar.' For more information regarding Lynn and Wendy's story and to order the book, "A Husband's Memoir: A Journey Through Alzheimer's," go to: This article is for informational purposes only and does not substitute for professional medical advice. If you are seeking medical advice, diagnosis, or treatment, please consult a medical professional or healthcare provider.
Yahoo
15 hours ago
- Yahoo
FDA-Approved Sleeping Pill Slows Alzheimer's Tangles in Pre-Clinical Trial
A drug used to treat insomnia has protected mice against the buildup of the tau protein found to clump abnormally in neurodegenerative diseases like Alzheimer's. This could lead to new ways to help slow the progress of these diseases. An increasing number of people are facing cognitive decline personally or in their loved ones. There are almost 10 million new cases of dementia globally each year, and despite decades of research, there are still few treatment options that provide clear benefits. So due to the links between Alzheimer's and poor sleep, Washington University neurologist Samira Parhizkar and colleagues investigated a central nervous system depressant, lemborexant, that was approved for use as a sleep aid by the FDA in December 2019. "We have shown that lemborexant improves sleep and reduces abnormal tau, which appears to be a main driver of the neurological damage that we see in Alzheimer's and several related disorders," explains Washington University neurologist David Holtzman. The role of amyloid beta proteins in Alzheimer's has been controversial, but they're not the only proteins implicated in the disease. Tau proteins normally contribute to the structure of brain cells, but past research has linked abnormal ones with the rate of brain atrophy in animal models. "The antibodies to amyloid that we now use to treat patients with early, mild Alzheimer's dementia are helpful, but they don't slow the disease down as much as we would like," says Holtzman. "We need ways to reduce the abnormal tau buildup and its accompanying inflammation, and this type of sleep aid is worth looking at further." But when the researchers compared lemborexant with another sleep aid, zolpidem, the results were unexpected. Mice receiving lemborexant retained up to 40 percent more volume in their memory-forming hippocampus than those who received zolpidem or no sleep aid at all. "What was surprising was that these effects were not seen with a standard sleep drug like zolpidem, which increases NREM sleep similarly to lemborexant," Parhizkar told Eric Dolan at PsyPost. "This suggests that the benefit is not just about more sleep, but rather how that sleep is promoted." The two sleep drugs work on different mechanisms, and that seems to be key to the protective effects. Lemborexant blocks orexin, a neuropeptide that regulates the sleep cycle, and when the team genetically knocked out orexin receptor 2 in mice, it reduced the buildup of tau in their brains. Strangely, though, the protective results of lemborexant were only seen in male mice, even though females were also tested. What's more, mouse studies don't always produce the same results in humans. Lemborexant has only been approved for short-term use in humans, so its long-term impacts as well as effectiveness in tau reduction still need to be investigated. While many questions remain to be answered, if the results seen in this study hold true, the researchers hope early intervention with a drug like lemborexant could potentially delay the progression of neurodegeneration. This research was published in Nature Neuroscience. Risk of Sleep Breathing Disorder Set to Rise 45% by End of Century Breakthrough: FDA Approves Injection to Prevent HIV Is It Gastro or Food Poisoning? Here's A Guide to Your Upset Stomach
